GlaxoSmithKline offers Merck up to €3.7bn to form immunotherapy venture

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 13:28

GlaxoSmithKline agreed to offer Merck up to €3.7bn (£3.2bn) to form a partnership to develop an immonutherapy for the treatment of cancer.

The deal involved GSK making an upfront payment to Merck of €300m regarding the treatment, known as M7824.

The German group would also be eligible for potential development milestone payments of up to €500m triggered by data from an M7824 lung cancer programme.

Merck would then be eligible for further payments upon successfully achieving future approval and commercial milestones of up to €2.9bn.

Eight related immuno-oncology clinical development studies were either ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers.

'Despite recent medical advances, many patients with difficult-to-treat cancers don't currently benefit from immuno-oncology therapies leaving them with limited treatment options,' GSK chief scientific officer Hal Barron said.

'M7824 brings together two different biological functions in a single molecule and we have observed encouraging clinical results in treating certain cancer patients, particularly those people with non-small cell lung cancer.'

'I'm excited by the potential impact this first-in-class immunotherapy could have on the lives of cancer patients.'

At 1:28pm: (LON:GSK) GlaxoSmithKline PLC share price was +19.9p at 1499.9p

Related content

GlaxoSmithKline blood cancer treatment meets primary objective in clinical trial

GlaxoSmithKline said a clinical study of its blood cancer treatment had met its primary goal.

'The two-arm study met its primary objective and demonstrated...

Fri, 23/08/2019 - 07:16

GlaxoSmithKline's JV ViiV Healthcare says trial of injectable HIV treatment met objectives

ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments...

Thu, 22/08/2019 - 07:41

GlaxoSmithKline submits renal anaemia drug application in Japan

GlaxoSmithKline said it had submitted an application for a drug that treats renal anaemia in patients with chronic kidney disease to the Japanese health regulator....

Wed, 21/08/2019 - 08:58

Ideagen is a structural growth story with plenty of opportunity


If the 10-year run of global economic expansion really is winding down then it makes sense for investors to look for structural growth drivers and...

Thu, 15/08/2019 - 00:00

The DNA of the FTSE 350


If you are new to stock market investing you may still have heard of the FTSE 100. It frequently appears on TV news bulletins and...

Thu, 15/08/2019 - 00:00